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Cancer is a worldwide public health problem. 
Despite considerable progress in its early 
diagnosis and treatment, successful remedy is 
alarmingly negligible. Cancer was thought to 
arise when cell growth exceeds the rate at 
which cells die, so that cells are dividing at an 
uncontrollable rate. There are more than 100 
different types of cancer. Most cancers are 
named for the organ or type of cell in which 
they start. Cancer types can be grouped into 
three broader categories. The main categories 
of cancer include: Carcinoma - (cancer that 
begins in the skin or in tissues that line or 
cover internal organs), Sarcoma - (cancer that 
begins in bone, cartilage, muscle, blood 
vessels, or other connective or supportive 
tissue), Leukemia - (cancer that starts in blood-
forming tissue such as the bone marrow and 
causes production of large numbers of 
abnormal blood cells and enter the blood). 
 In current anti-cancer therapy, drugs are 
administered though intravenous and oral route 
using conventional formulations like tablet, 
capsule and injectable. Sustained and targeted 
delivery of anti-cancer agents at the site of 
action is desired to maximize the killing effect 
during the tumor growth phase and avoiding 
the exposure to surrounding healthy cells for 
reducing the toxicity. It is also desired to 
maintain a steady state infusion of drug into 
the tumor interstitium to maximize the 
exposure to the dividing cells that results in 
tumor regression. (1) Conventional oral and 
injectable dosage forms of anti-cancer drugs 
are not able to do this due to short biological 
half-life, narrow therapeutic index, poor oral 
bioavailability and formulation difficulties like 
poor water solubility, stability and high 
molecular weight. (2) In the recent past, 
advances in novel drug delivery system 
(NDDS) have resulted in use of several 
colloidal carriers such as liposomes, niosomes, 
microemulsion, nanoemulsion, microsphere 
and polymeric micelles for sustained and 
targeted delivery of anti-cancer agents. Further 
revolutions in nanotechnology increased the 
hope for rationalization in therapeutic options 
for rationalized delivery of anti-cancer agents 
with high efficacy. Development of NDDS 
based formulation for delivery of anti-cancer 
drugs is a recent topic of research in 
Pharmaceutical Industries. Nanoxel(R), 
nanoparticles based formulation for paclitaxel 
from Dabur and Abraxane(R), albumin based 
ABSTRACT 
In the recent scenario of the world there are millions of the people are suffering from the various types of 
cancer. To cure the cancer immunotherapy, radiation therapy, chemotherapy, surgery and hormonal therapy 
treatments are used.  In treatment of cancer the convectional approaches are used which can adversely affect to 
normal cells on the body. Also, the side effects of this treatments are damage the immune system of the patient. To 
overcome such problems with the conventional treatment of the cancer the targeted drug delivery system is 
developed, in such oral delivery of drug at the particular location of tumor at perfect time with specific dosage.   
This review includes the development of the new targeted drug delivery system and its limitations. 
Keywords: Cancer pathophysiology, Drug Delivery, Targeted drug delivery, anti-cancer drugs. 
Rajashri et al.                                                Himalayan Journal of Health Sciences                                     ISSN: 2582 - 0737 
© 2020 HJHS Journal                                                                 2020; 5(2) Page 20  
formulation for paclitaxel from Abraxis 
BioScience Inc., USA is the well-known 
commercial products Table 1.  
Table 1. Commercially available NDDSs for anti-cancer drugs 
Drug name Novel system Brand name 
Paclitaxel Polymeric nanoparticles gel Nanoxel 
Doxorubicin Liposomal injection Doxil 
Doxorubicin PEGylated liposomal injection Lipo-dox 
Doxorubicin PEGylated liposomal injection Myocet 
Doxorubicin PEGylated liposomal injection Lip-Dox 
Paclitaxel Albumin bound particles Abraxane 
Cytarabine Liposomal injection Depocyt 
The reason behind the interest of 
pharmaceutical company in this area of 
research is due to high cost of treatment, 
required repeated administration for prolong 
period of time and exponential increase in 
number of cancer patients. In the present 
section of review of literature, we have 
explored the possible use of different carrier 
systems for sustained and targeted delivery of 
anti-cancer agents with their relative 
advantages, limitations and commercial 
importance. This information will help the 
drug delivery scientist in designing the better 
formulation for delivery of anti-cancer drugs. 
2. Pathophysiology of Cancer 
Cancer is basically a disease of failure of 
regulation of cell cycle. In cancer, the cells 
transform from normal into cancer cells mainly 
due to alterations in genes which regulate the 
cell growth and differentiation. The altered 
genes are divided into two broad categories. 
Oncogenes (e.g. Her 2, c-Myc, etc.) and tumor 
suppressor genes p53 Rb). Oncogenes are the 
genes which promote the cell growth and 
reproduction. Second class of genes inhibits 
the cell division. The cancerous transformation 
can occur through the formation of novel 
oncogenes, the inappropriate over expression 
of normal oncogenes or disabling of tumor 
suppressor genes. Genetic changes can occur at 
different levels and by different mechanisms. 
The gain or loss of an entire chromosome can 
occur through errors in mitosis. Cell division is 
a genetic process in which a cell passes its 
genes onto two daughter cells, each of which is 
a clone or exact of itself. Sometimes, this 
orderly process goes wrong, the genes in a cell 
may suffer a mutation or some mistakes may 
occur in DNA replication and recombination 
during cell division. Genetic changes are more 
commonly by mutations, which are changes in 
the nucleotide sequence of genomic DNA. 
Large-scale mutations involve the deletion or 
gain of a portion of a chromosome. Genomic 
amplification occurs when a cell gains many 
copies (often 20 or more) of a small 
chromosomal locus, usually containing one or 
more oncogenes and adjacent genetic material. 
Translocation occurs when two separate 
chromosomal regions become abnormally 
fused, often at a characteristic location. Small-
scale mutations include point mutations, 
deletions, and insertions, which may occur in 
the promoter region of a gene and affect its 
expression, or may occur in the gene's coding 
sequence and alter the function or stability of 
its protein product. Disruption of a single gene 
may also result from integration of genomic 
material from a DNA virus or retrovirus, and 
resulting in the expression of viral oncogenes 
in the affected cell and its descendants. 
Replication of the enormous amount of data 
contained within the DNA of living cells will 
probabilistically result in some errors 
(mutations). Complex error correction and 
prevention is built into the process, and 
safeguards the cell against cancer. If 
significant error occurs, the damaged cell can 
"self-destruct" through programmed cell death, 
termed apoptosis. If the error control processes 
fail, then the mutations will survive and be 
passed along to daughter cells. Some 
environments make errors more likely to arise 
and propagate. Such environments can include 
the presence of disruptive substances called 
carcinogens, repeated physical injury, heat, 
ionising radiation, or hypoxia. The 
transformation of normal cell into cancer is 
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akin to a chain reaction caused by initial errors, 
which compound into more severe errors, each 
progressively allowing the cell to escape the 
controls that limit normal tissue growth. This 
rebellion-like scenario becomes an undesirable 
survival of the fittest, where the driving forces 
of evolution work against the body's design 
and enforcement of order. Once cancer has 
begun to develop, this ongoing process, termed 
clonal evolution drives progression towards 
more invasive stages. Figure 1 shows 
pathophysiology of cancer. 
 
 
Figure 1. Normal cells and cancer cell difference 
3. Problems in Conventional Delivery of 
Anti-Cancer Drugs  
In the field of medicine, the oncology is widely 
growing subspecialty. There are various 
treatments as immunotherapy, radiation 
therapy, chemotherapy, surgery and hormonal 
therapy used to treat the cancer. However, 
chemotherapy treatment for cancer is mostly in 
use but it has many side effects. Various anti-
cancer drugs are listed in Table 2. Currently, 
the intravenous and convectional oral routs are 
used for administration of the anti-cancer drug.  
The listed drugs in the Table 3 is marketed 
anti-cancer drugs convectional dosage forms. 
The administrative routs for this drug have 
significant side effects on the healthy tissues in 
organs because of the non-specific delivery. 
(3) On the other hand, oral administration of 
the drug delivery has potential and helps to 
improve patient life. Also, this method for drug 
delivery are most economical and effortable 
but it has some limitations such as low 
therapeutic, poor patient compliance, short 
biological half-life, development of resistance 
and inability to achieve therapeutic 
concentrations at the target site. (4-5)  
Another major limitation of the oral 
administration is the variability in 
bioavailability of substantial patient after 
taking treatment.  The significant difference is 
observed in pharmacology effects because of 
the difference in absorption profile.   
Intravenous route also has many limitations 
particularly as this route delivers potentially 
high concentration of drug to normal tissues 
which results in toxicity. 
Several anti-cancer agents are biologically 
reactive and may trigger the release of various 
vasoactive substances, sometimes resulting in 
life threatening reactions. 
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 Acute leukemia, 
Choriocarcinoma, non 
Hodgkin’s lymphoma, 
colon, urinary baldder, 
liver and breast 
cancers 





 Inhibition of 
thymidilate 
synthase 
 Inhibition of 
DNA 
polymerase 
 Inhibition of 
nucleotide 
metabolism 
Table 3 Marketed conventional dosage forms of anti-cancer drugs 
Drug Dosage Form Brand Company 
Busulfan Tablet Busulfex Orphan drug company 
Docetaxel Injection Taxotere Sanofi Aventis 
Vincristine Injection Oncovin Genus Pharmaceuticals 
Limited 
Tamoxifen Tablet Nolvadex AstraZeneca Pharmaceuticals 
Chlorambucil Film coated 
tablet 
Amcil Amronco life sciences limited 
5-FU Capsules Fluracil Biochem Pharmacuticals 
 
4. Novel Drug Delivery Systems for Anti-
Cancer Drug Delivery  
As discussed in the above section the 
conventional treatment for the cancer is killing 
the healthy tissues in the body with cancer 
cells because cytotoxic agent’s travel with it. 
Due to its side effect patient can feel 
unpleasant side effects such as hair loss to 
nausea and this treatment can damage the 
immune system of the patient. The 
development and research are ongoing on 
reducing the side effects of cancer treatment. 
(6) One of the potential treatments is target 
drug delivery system at the right pace with 
required amount. The new development of the 
targeting drug delivery the new innovations in 
delivering cancer therapies are the 
development of a technology platform which 
targets the therapy only to the tumor; leaving 
normal cells undamaged Table 4. 
Extensive Survey on Different Approaches 
Reported for Sustained and Targeted 
Delivery of Anti-Cancer Agents 
Nanoparticles 
To compare the anti-tumor efficacy of 
paclitaxel loaded nano particles and delivered 
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intratumorally in comparison to marketed Cremophor EL based paclitaxel injection. 
Table 4 Summary of findings reported for altering the biodistribution of anti-cancer drugs 
Drug Name System Finding Reference 
Tamoxifen Nanoparticles  Increased level of accumulation of the 
drug within tumor 
(1) 
Paclitaxel Microemulsion  Enhanced anti-tumor activity 
 Total inhibition of cell growth upto 144h 
(7) 
Paclitaxel Nano particles  Achieved larger cytotoxicity and smaller 
IC50 over Commercial preparation 
(8) 
Doxorubicin Human albumin 
serum (HAS)- 
Nanoparticles 
 Diminish the toxicity and overcome the 




Nanospheres  Found as promising carrier with altered 
biodistribution 
(10) 
Docetaxel Water Emulsion 
system 
 Enhanced accumulation of docetaxel in a 
model tumor 
 4.5 fold increase accumulation of 







 3.7 to 17.0 times increased killing ability 
shown by formulated preparation than 




Niosomes  4 to 8 folds enhanced drug penetration (13) 
 
It was found that developed nanoparticles 
sustained the drug release, increased cellular 
concentration and enhanced anti-tumor 
efficacy of paclitaxel compared to marketed 
formulation. (14-15)  
To prepared paclitaxel loaded polymeric 
nanoparticles with an aim to achieve targeted 
delivery of paclitaxel. Nanoparticles were 
developed by using biodegradable methoxy 
poly(ethylene glycol)-poly-(ε-caprolactone) 
(MPEG-PCL) diblock copolymer. Paclitaxel 
loaded nanoparticles had shown very high 
entrapment efficiency above (95%) and 
sustained release during in vitro experiments. 
The maximum tolerated dose (MTD) of 
paclitaxel loaded nanoparticles after single 
dose in Balb/c mice was above 80 mg PTX/kg 
body weight (b.w), which was 2.6-fold higher 
than that of Taxol(R) (30 mg paclitaxel/kg 
b.w). The higher concentration of paclitaxel 
found in tumor tissue in paclitaxel loaded 
nanoparticles administered group in 
comparison to taxol treated group. It was 
concluded that nanoparticles based paclitaxel 
formulation is good alternative to conventional 
formulation for controlled delivery of 
paclitaxel. (16)  
Studied the efficiency of doxorubicin loaded 
iron oxide nanoparticles in comparison to 
doxorubicin drug solution. The results 
indicated that doxorubicin nanoparticles were 
readily taken up by drug resistant cells and 
greater reduction in cell viability was found 
than cell treated with doxorubicin solution. 
The results suggest that doxorubicin 
nanoparticles could improve the efficiency of 
chemotherapy. (17)  
To developed the nanoparticles that facilitate 
intracellular delivery of nanoparticles within 
the tumor. Hydrophobically modified glycol 
chitosan nanoparticles conjugated with 
interleukin-4-receptor (IL-4R) binding 
peptides were developed and were tested in 
mice bearing positive tumors. The results 
indicated enhanced cellular uptake of 
nanoparticles in tumors in comparison to 
conventional approach. (18) Developed natural 
polymer based etoposide loaded nanoparticles 
attached with folic acid as ligand. These nano 
particles found more effective on HeLa cell 
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line than etoposide loaded plain nanoparticles 
and shown more potential as a targeted cancer 
therapy. (19) 
To prepared tyrosine derived nanospheres 
loaded with paclitaxel and evaluated the 
toxicity and efficacy of this drug delivery 
system in comparison to Cremophor EL based 
marketed formulation. The results of this study 
suggested that nanospheres based formulation 
significantly increased the maximum tolerated 
dose and enhanced anti-tumor efficacy in 
tumor breast cancer cell lines. (20) 
The above studies suggested that nanoparticles 
for drug delivery of anti-cancer drugs are a 
useful approach to provide site specific and 
controlled release of drug at the target tumor 
site which ultimately improves the efficiency 
of chemotherapy at lower dose. 
Emulsion systems 
To prepared paclitaxel micro emulsion 
containing reduced amount of Cremophor EL 
and evaluated pharmacokinetics, 
biodistribution and in vivo anti-tumor efficacy. 
The antitumor efficacy of the paclitaxel 
microemulsion in OVCRA-3 and A 549 
tumor-bearing animals was similar to that of 
paclitaxel marketed formulation. The incidence 
and degree of allergic reactions exhibited by 
the paclitaxel microemulsion group, with or 
without premedication, were significantly 
lower than those in the paclitaxel injection 
group. (21) 
To prepared the Vinorelbine-loaded lipid 
emulsion (VLE) and compared its toxicity and 
its anti-tumor efficiency in comparison to 
conventional marketed formulation. VLE 
significantly reduced the toxicity in 
comparison to marketed formulation. 
Comparable anti-tumor efficiency was also 
obtained in comparison to marketed 
formulation.  
To developed hydroxylcamptothecin (HCPT) 
loaded emulsion spun fibers and evaluated 
anti-tumor efficiency by in vitro and in vivo 
method. In vitro cytotoxicity tests on HCPT-
loaded electrospun fibers indicated over 20 
times higher inhibitory activity against HepG2 
cells than free HCPT. Similarly, HCPT-loaded 
fibers indicated superior in vivo antitumor 
activities and fewer side effects than free 
HCPT. The above results demonstrate the 
potential use of emulsion electrospun fibers as 
drug carriers for local treatment of solid 
tumors. (22) 
The above studies suggested that emulsion 
systems are safer to administer and easier to 
prepare but some problems such as difficulty 
in particle size reduction and low entrapment 
efficiency limit the application of emulsion 
systems in drug delivery. 
Polymeric micelles 
Polymeric micelles are currently recognized as 
one of the most promising modalities of drug 
carriers. (23-24) Polymeric micelles have a 
unique core-shell structure, in which an inner 
core serving as a nano container of 
hydrophobic drugs surrounded by an outer 
shell of hydrophilic polymers, such as poly 
(ethylene blycol) PEG, and have demonstrated 
longevity in the bloodstream and effective 
tumor accumulation after their systemic 
administration. (25-26) 
To prepared Docetaxel-loaded methoxy-
poly(ethylene glycol)-block-poly(d, l-lactide) 
(m PEG-PDLLA) micellar formulation and its 
pharmacokinetics, efficacy, and toxicity were 
evaluated in comparison with marketed 
paclitaxel formulation Taxotere® in preclinical 
studies. Results of study indicated that 
prepared micellar formulation reduces side 
effects while retaining anti-tumor efficiency in 
cancer patients in comparison to Taxotere®. 
(27) 
The above studies indicated that polymeric 
micelles are good colloidal nanocarriers for the 
targeting of poorly water soluble drugs. Due to 
their hydrophilic shell and small size they can 
accumulate in tumoral tissues.  
Solid lipid nanoparticles (SLN) 
To prepared and investigated tumor targeting 
potential of surface tailored solid lipid 
nanoparticles (SLNs) loaded with anti-cancer 
drug doxorubicin. Results revealed that 
formulation exhibited a biphasic pattern 
characterized by initial rapid release of the 
drug followed by slow and prolonged release. 
Significantly higher cytotoxicity of 
doxorubicin loaded SLNs found in comparison 
to doxorubicin drug solution in A549 cell line. 
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The biodistribution profile exhibited that SLNs 
were able to deliver a higher concentration of 
doxorubicin in tumor mass. (28) 
To prepare solid lipid nanoparticles loaded 
with a promising chemo preventive drug 
Resveratrol. The results indicated that 
intracellular delivery of drug significantly 
increased with this carrier system in 
comparison to drug solution and finally 
enhanced cytostatic effect was obtained. (29) 
Administration of anti-cancer drugs by using 
solid lipid nanoparticles is a promising 
approach. Many problems in the 
administration of anti-cancer drugs like non 
target organ toxicity, pitiable specificity and 
high incidence of drug resistant tumor cells are 
at least partially overcome by delivering anti-
cancer drugs by using solid lipid nanoparticles. 
Liposomes 
To prepared liposomes containing histone 
deacetylase inhibitors (HDACi) and optimized 
the formulation. They have evaluated the cell 
viability of developed formulation in breast 
cancer cell lines SKBR3 and MCF-7 by 
administering without drug loaded liposomes 
and drug loaded formulation. The observed 
results indicate that no cytotoxicity of 
unloaded liposomes and altered breast cancer 
cell viability found with drug loaded liposomes 
in comparison to drug solution. (30)  
To optimized the liposomes for the 
administration of mitoxantrone (MTO) with 
the aim to improve the therapeutic effect of 
drug. The anti-cancer activity was evaluated in 
peritoneal carcinomatosis model. This system 
exhibited the strongest binding affinity for 
MTO, the highest anti-cancer activity and the 
lowest toxicity. This cardiotoxcity of MTO 
was significantly reduced in comparison to 
drug solution. (31) 
To prepare the RGD grafted docetaxel 
liposomes and evaluated in vitro cytotoxicity, 
mechanism of cell death, in vivo 
pharmacokinetic and biodistribution behavior 
of formulation. The results indicated sustained 
intracellular release of drug from liposomal 
system with site specific distribution of drug to 
tumor and enhanced anti-tumor activity. 
(32,33) 
To synthesized a novel polyethylene glycol-
phosphatidylethanolamine (PEG-PE) 
conjugate with the Triphenylphosphonium 
(TPP) group attached to the distal end of the 
PEG block (TPP-PEG-PE). This conjugate was 
incorporated into the liposomal lipid bilayer, 
and the modified liposomes were studied for 
their toxicity, mitochondrial targeting, and 
efficacy in delivering paclitaxel (PTX) to 
cancer cells. PTX-loaded TPP-PEG-L 
demonstrated enhanced PTX-induced 
cytotoxicity and anti-tumor efficacy in cell 
culture and mouse experiments compared to 
PTX-loaded conventional liposomes. (34) 
The above studies in which liposomal drug 
delivery systems were studied indicated that 
this approach has provided an opportunity to 
enhance the therapeutic efficiency of drugs by 
altering their solubility and biodistribution. 
Some studies suggested that liposomal systems 
significantly increased the cytotoxicity of the 
anti-cancer drugs when administered by using 
liposomes. (35, 36) 
5. Conclusions  
Novel drug delivery systems of anti-cancer 
drugs will alter the pharmacokinetic properties 
of drug accompanied by elimination or 
reduction of nonspecific toxicities typically 
associated with chemotherapy. They will 
provide versatile and straight forward approach 
for improving the physiological and 
pharmacological responses of the drug and 
overcome the problem of drug solubility. With 
use of novel drug delivery systems, it is 
possible to reduce the dose of drug and at the 
same time cost of cancer chemotherapy. Novel 
approaches to cancer treatment not only 
supplement the conventional chemotherapy 
and radiotherapy but also prevent damage to 
normal tissues and prevent drug resistance. 
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